Brii Biosciences Limited, wani kamfani na kasa da kasa da ke samar da sabbin hanyoyin magance cututtukan da ke da manyan bukatu na likitanci da kuma nauyin kiwon lafiyar jama'a, a yau ya sanar da cewa, Hukumar Kula da Kayayyakin Kiwon Lafiya ta kasar Sin (NMPA) ta kasar Sin ta ba da amincewar kamfanin na rigakafin cutar sankarau na monoclonal (mAb). far, haɗin amubarvimab / romluseimab (a da BRII-196 / BRII-198 haɗin gwiwa), don jiyya a cikin manya da marasa lafiya na yara (shekaru 12-17 mai nauyin aƙalla 40 kg) tare da nau'in COVID-19 mai laushi da na al'ada a babban haɗari. don ci gaba zuwa cututtuka mai tsanani, ciki har da asibiti ko mutuwa. Alamun marasa lafiya na yara (shekaru 12-17 suna yin awo aƙalla 40 kg) yana ƙarƙashin izini na sharadi.
Masu biyan kuɗi suna shiga nan Danna nan don biyan kuɗi FREE
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Brii Biosciences Limited, a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that the National Medical Products Administration (NMPA) of China has granted approval of the company’s monoclonal neutralizing antibody (mAb) therapy, the amubarvimab/romlusevimab combination (previously BRII-196/BRII-198 combination), for the treatment in adults and pediatric patients (age 12-17 weighing at least 40 kg) with mild and normal type of COVID-19 at high risk for progression to severe disease, including hospitalization or death.
- The indication of pediatric patients (age 12-17 weighing at least 40 kg) is under a conditional approval.
- Biyan kuɗi kyauta ne.
